- Active not recruitingPHASE2
Evorpacept (ALX148) in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03)
This study looks at a new drug, evorpacept, combined with an existing one, pembrolizumab, for advanced head and neck cancer. It aims to see if this combination works better than pembrolizumab alone for patients who haven't had treatment for advanced stages of their cancer. It's a Phase 2 trial, meaning it's still in earlier stages of testing.
For: Head and Neck Cancer · Head and Neck Squamous Cell CarcinomaUnited States · Australia · Belgium - RecruitingPHASE1, PHASE2
Isatuximab in Combination With Novel Agents in RRMM - Master Protocol
This study looks at new drug combinations with isatuximab and other treatments for a type of blood cancer called multiple myeloma. It aims to find better ways to treat patients whose cancer has come back or hasn't responded to previous treatments.
For: Plasma Cell Myeloma RefractoryUnited States · Australia · France - Active not recruitingPHASE2
Evorpacept (ALX148) in Combination With Pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-04)
This study looks at a new drug, evorpacept, combined with pembrolizumab and chemotherapy for advanced head and neck cancer. It aims to see if this new combination is effective for patients who haven't had treatment for their advanced disease.
For: Head and Neck Cancer · Head and Neck Squamous Cell CarcinomaUnited States · Australia · Belgium